Navigation Links
Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea

alarming rise in the incidence of disease, higher numbers of patients with complications and more frequent failures of standard antibiotic therapy.

Tolevamer is designed to bind and neutralize the toxins released by C. difficile that damage the intestine. A non-antibiotic approach has the potential to treat CDAD and reduce the number of disease recurrences, resulting in improved quality of life for the patient and significant savings to the healthcare system.

About the PACT Study

The PACT study, which involved more than 1,100 patients at approximately 300 sites in North America, Europe, and Australia, is the largest of its kind ever to be conducted for CDAD. In this trial, tolevamer was compared to metronidazole and vancomycin. Aside from testing tolevamer's efficacy, this was also the first large, rigorously designed, multi-center clinical study that will compare the efficacy of the current standards of care.

About Clostridium difficile

C. difficile proliferates in the setting of altered normal colonic bacterial flora, most commonly due to the administration of broad-spectrum antibiotics. Once established in the colon, C. difficile produces toxins that disrupt the intestinal lining, causing cell death and inflammation that result in diarrhea and colitis.

Earlier studies have shown that even after successful treatment with the current standard of care, approximately 20 percent of patients experience a recurrence of CDAD potentially requiring repeat hospitalization. In addition, a subset of patients with CDAD develop multiple recurrences of the disease, with symptoms that may persist for years.

About Genzyme One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,000 employees in locations spanning the globe and 2006 revenue
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genzyme Announces Results of Clinical Trial of Hylastan
2. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:10/22/2014)... Moms are ready to live the "measured ... their kids, according to the results of the BabyCenter® ... Mobile for Moms, the latest installment in BabyCenter,s 21 ... pregnancy and parenting web and mobile destination worldwide, conducted ... surveyed say they can,t think of a reason not ...
(Date:10/22/2014)... -- A new report by Allied Market ... End user, Application and Geography) - Size, Share, Global ... Segmentation and Forecast, 2013 - 2020", considers commercial aspects ... trends tracked, it is anticipated that the market is ... registering a CAGR of 6.2% from 2014 to 2020. ...
(Date:10/22/2014)... , October 22, 2014 ... ), a clinical-stage pharmaceutical company focused on ... reported positive top-line clinical results from its Phase ... oral insulin capsules, to treat type 1 diabetes. The ... States under a U.S. Food and ...
Breaking Medicine Technology:BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. ... in vitro fertilization (IVF) -- the incubation of embryos in ... device inside the vagina, new research suggests. Scientists from ... an INVOcell, might sharply cut costs for pricey IVF procedures ... accessible to those who don,t live near big-city assisted reproduction ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... October 20, 2014 ASCNYC (ascnyc.org) ... that helps New Yorkers living with HIV/AIDS and ... health, housing, recovery and self-sufficiency. Each year, ASCNYC ... local community through their tireless efforts. , ... Shapses , has been selected as this year’s ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ... platform to think outside the bra. She doesn’t try to ... raise awareness about women’s other lady parts. , "We have ... the color pink and everybody knows what you’re talking about,” ... it has not been won when it comes to gynecologic ...
Breaking Medicine News(10 mins):Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3
... Ind., May 7 Conseco, Inc. (NYSE: ... regulators and two of,its insurance subsidiaries: Conseco Senior ... Company. The settlement concludes a,multistate market conduct examination ... to long-term care claims practices and,procedures, complaint handling, ...
... May 7 Yesterday H. Con.,Res. 342 was introduced ... opposing the Food and Drug Administration,s (FDA) decision to,restrict ... by women to alleviate the symptoms of menopause. The ... pharmacies in January asking them to,cease and desist with ...
... were missed, more doses taken on time , , WEDNESDAY, May ... are less likely to miss doses when reminded by an ... and announces the number of pills to take and how ... was funded by the National Institute on Aging, was presented ...
... AFL ) announced today that it will webcast its annual Financial,Analysts ... operations in Japan and in the United States as well as ... as,follows:, Wednesday, May 14, 2008 8:00 p.m. ... Daniel P. Amos, Chairman & ...
... May 7 Amneal Pharmaceuticals is pleased,to announce ... Primidone,Tablets (50/250mg), Cyclobenzaprine Tablets (10mg) and Demeclocycline,Tablets (150/300mg) ... products,were filed during 2007 using the FDA,s evolutionary ... months., Demeclocycline HCl Tablets USP, in strengths ...
... NHS Choices ( http://www.nhs.uk ), the new,digital ,front ... Well bundle aimed to,help people stay healthy during ... information, the Live Well Travel health guide,( http://www.nhs.uk/livewell/travelhealth/Pages/Travelhealthhome.aspx ... and provides them,with clinically approved guidance to help ...
Cached Medicine News:Health News:Conseco Reaches Settlement of Multistate Market Conduct Examination 2Health News:Electronic Pillbox Helps Seniors Stick to Drug Regimens 2Health News:Electronic Pillbox Helps Seniors Stick to Drug Regimens 3Health News:Aflac Incorporated to Webcast 2008 Financial Analysts Briefing 2Health News:Aflac Incorporated to Webcast 2008 Financial Analysts Briefing 3Health News:Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format 2
Multispot HIV-1/HIV-2 is a rapid indirect EIA using recombinant and peptide antigens for simultaneous detection and differentiation of anti-HIV-1 and anti-HIV-2 antibodies in human serum or plasma....
Bio-Rad's Genetic Systems™ HBsAg EIA 3.0 screening and confirmatory assays offer outstanding sensitivity and early detection of HBV infection, helping to meet your testing criteria....
The most compact revolutionary innovation in hematology. 3 Part DIFF + CRP measurement on whole blood....
... Evolis™ is a self contained microplate ... based EIA assays. The system is dedicated ... encountered in todays busy laboratory. The system ... of EIA assays that satisfy their microplate ...
Medicine Products: